- Home
- » Tags
- » BRAF (gene)
Top View
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma
- Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma
- Target Genes Regulated by Hsa-Mir-21, by Hsa-Mir-203, by Hsa-Mir-21 and by Hsa-Mir-143
- Comprehensive Review on the Clinical Relevance of Long Non-Coding Rnas in Cutaneous Melanoma
- Hereditary Cancer Panel Descriptions
- Management of Intracranial Melanomas in the Era of Precision Medicine
- Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation
- And BRAFV600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling
- BRAF Cooperates with PI3K Signaling, Independent of AKT, to Regulate
- Signature BRAF Mutations Kit Protocol Guide
- Pkc Epsilon Is Required for Kras-Driven Lung Tumorigenesis
- Mutations in the RAS-BRAF-MAPK-ERK Pathway
- Overcoming Resistance to BRAF Inhibitors
- Genetic Inactivation Or Pharmacological Inhibition of Pdk1 Delays Development and Inhibits Metastasis of Braf V600E::Pten–/– Melanoma
- MEK Inhibitors Block Growth of Lung Tumours with Mutations in Ataxia–Telangiectasia Mutated
- BRAF Testing for Colorectal Cancer
- Genomic Profiling and New Immunotherapies: an Oncologist’S Perspective
- Dual Inhibition of BRAF and Mtor in BRAFV600E-Mutant Pediatric, Adolescent, and Young Adult Brain Tumors
- Protein Kinase C Pharmacology: Refining the Toolbox
- Kin-2787, Is Active in Class Ii and Class Iii Braf Mutant Models
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large
- BRAF Gene B-Raf Proto-Oncogene, Serine/Threonine Kinase
- Functional Role of Protein Kinase C Alpha in Endometrial Carcinogenesis
- PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas
- The 14-3-3 Proteins As Important Allosteric Regulators of Protein Kinases
- Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
- Combating Acquired Resistance to MAPK Inhibitors in Melanoma by Targeting Abl1/2-Mediated Reactivation of MEK/ERK/MYC Signaling
- Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
- Combined PKC and MEK Inhibition in Uveal Melanoma with GNAQ and GNA11 Mutations
- New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Leah J
- Pkc Isozymes in Lung Cancer Development and Therapy Resistance
- The Role of Pim-2 in Apoptotic Signal Transduction Pathway of Hepatocellular Carcinoma
- Molecular Genetic Testing for BRAF Mutations
- Cobas® 4800 BRAF V600 Mutation Test C(Obase 2 for in VITRO DIAGNOSTIC USE
- BRAF in Melanoma Answering Questions, Addressing Misconceptions
- DNA Methylation Instability by BRAF-Mediated TET Silencing And
- BRAF Mutation Analysis
- Cancer Genetics of Sporadic Colorectal Cancer: BRAF and PI3KCA Mutations, Their Impact on Signaling and Novel Targeted Therapies
- Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Suppresses
- Markers of MEK Inhibitor Resistance in Low
- Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course
- Characterization and Clustering of Kinase Isoform Expression in Metastatic Melanoma
- Mutations of the BRAF Gene in Squamous Cell Carcinoma of the Head and Neck
- Autophagy Inhibition in BRAF-Driven Cancers
- JUN Dependency in Distinct Early and Late BRAF Inhibition Adaptation States of Melanoma
- Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
- A New Mechanism of BRAF Activation in Human Thyroid Papillary Carcinomas
- Management of Intracranial Melanomas in the Era of Precision Medicine
- Systems Biology Analysis of Mitogen Activated Protein Kinase Inhibitor Resistance in Malignant Melanoma
- Truncation and Motif Based Pan-Cancer Analysis Highlights Novel Tumor
- Pathway-Directed Therapy in Multiple Myeloma
- B-Raf and the Inhibitors: from Bench to Bedside Tiangui Huang1, Michael Karsy1,2, Jian Zhuge1, Minghao Zhong1 and Delong Liu3*
- Molecular Features and Gene Expression Signature of Metastatic Colorectal Cancer (Review)
- PDK1) As a Key Regulator of Cell Migration and Cancer Dissemination
- Study of the Cooperative Effect of UVR, BRAF and LKB1 in Melanoma Phd Thesis
- C-RAF Mutations Confer Resistance to RAF Inhibitors
- Development and Characterization of Novel Raf Dimer Inhibitors to Target Brafv600e Inhibitor Resistance
- Axl-Mediated Activation of TBK1 Drives Epithelial Plasticity in Pancreatic Cancer Victoria H
- Whole-Exome Sequencing of Pancreatic Cancer Defines Genetic
- Advances in Cyclin-Dependent Kinase Inhibitors for the Treatment of Melanoma
- Beyond RAS and BRAF: a Target Rich Disease That Is Ripe for Picking
- Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
- Roles for the IKK-Related Kinases TBK1 and IKK in Cancer